Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

[1]  K. S. Hall,et al.  Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial , 2016, The Lancet. Oncology.

[2]  S. Ferrari,et al.  Telangiectatic osteosarcoma: a review of 87 cases , 2016, Journal of Cancer Research and Clinical Oncology.

[3]  P. Meltzer,et al.  Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Sydes,et al.  Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Jonathan W. Bartlett,et al.  Multiple Imputation of Covariates by Substantive-model Compatible Fully Conditional Specification , 2015 .

[6]  K. S. Hall,et al.  EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  A. Berner,et al.  Time-trends on incidence and survival in a nationwide and unselected cohort of patients with skeletal osteosarcoma , 2014, Acta oncologica.

[8]  K. S. Hall,et al.  High‐dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: Final results of the ISG/SSG II study , 2014, Pediatric blood & cancer.

[9]  C. Fletcher.  The evolving classification of soft tissue tumours – an update based on the new 2013 WHO classification , 2014, Histopathology.

[10]  David M. Thomas,et al.  Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Paul A Meyers,et al.  Outcome for adolescent and young adult patients with osteosarcoma , 2012, Cancer.

[12]  S. Ferrari,et al.  Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  L. Trani,et al.  Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  L. Mirabello,et al.  Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.

[15]  S. Ferrari,et al.  High grade osteosarcoma of the extremities with lung metastases at presentation: Treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions , 2008, Journal of surgical oncology.

[16]  Paul A Meyers,et al.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Sydes,et al.  International collaboration is feasible in trials for rare conditions: the EURAMOS experience. , 2007, Cancer treatment and research.

[18]  D. Vanel,et al.  SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. , 2007, European journal of cancer.

[19]  Piero Picci,et al.  Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy , 2006, Cancer.

[20]  A. Petrilli,et al.  Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Kleinerman,et al.  Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  W. Winkelmann,et al.  Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Smeland,et al.  Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII , 2003 .

[24]  E. van Marck,et al.  Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup. , 2002, European journal of cancer.

[25]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Ferrari,et al.  Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Bielack,et al.  Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  A. Huvos,et al.  Osteogenic sarcoma with clinically detectable metastasis at initial presentation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  W. Winkelmann,et al.  Osteosarcoma: the COSS experience. , 2009, Cancer treatment and research.

[30]  S. Ferrari,et al.  Primary chemotherapy and delayed surgery for non-metastatic telangiectatic osteosarcoma of the extremities. Results in 28 patients. , 1994, European journal of cancer.